Genoscience Pharma has received approval from the US Food and Drug Administration (FDA) to begin a Phase Ib/IIa study of GNS561 to treat hepatocarcinoma (HCC), the most common form of liver cancer.

The trial represents the first-in-human study to be carried out as part of the investigational new drug (IND) protocol approved by FDA.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It intends to evaluate the safety, activity and pharmacokinetics of escalating doses of GNS561, which is a solute carrier transporter (SLCT) inhibitor.

Up to 36 patients in six groups will be included during the dose escalation phase, as well as additional patients in the continuation phase to obtain a total of 20 evaluable subjects at the recommended dose.

The FDA approval of our first IND application is a major milestone for Genoscience Pharma.

“We believe that GNS561, acting through a novel mechanism of action, has the potential to change the treatment paradigm of HCC.”

Genoscience Pharma CEO Philippe Halfon said: “The FDA approval of our first IND application is a major milestone for Genoscience Pharma.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This strengthens our position as a drug discovery and development company focused on the development of innovative anti-cancer drugs for the betterment of patients.

“We believe that GNS561, acting through a novel mechanism of action, has the potential to change the treatment paradigm of HCC.”

Currently, more than 780,000 new cases of liver cancer are estimated to be diagnosed annually, making the disease to be the fifth most common cancer worldwide.

Liver cancer is also claimed to be the second leading cause of cancer-related deaths globally, accounting for around 746,000 deaths every year.